Drug Trial Radar · NCT07428642
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
168
Actual
Start
Sep 1, 2020
Primary completion
Dec 3, 2025
Study completion Dec 3, 2025
Sponsor
- Lead sponsor
- First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Second Affiliated Hospital of Wenzhou Medical University; Ningbo No. 1 Hospital; Lishui Country People's Hospital; Sun Yat-Sen University Cancer Center
- First posted
- Feb 24, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter retrospective study developed and validated a prediction model based on PSMA PET/CT and routine clinical information to estimate early treatment response in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving first-line standard therapy. Existing PSMA PET/CT scans were used to quantify tumor burden, and imaging metrics were combined with baseline clinical factors, including laboratory results and disease characteristics, to build an interpretable model for predicting the likelihood and timing of achieving a deep PSA response (PSA ≤ 0.2 ng/mL) after initiation of first-line treatment. All data were collected from medical records and imaging obtained as part of routine care; no additional tests or treatments were required. The objective was to improve risk stratification and support individualized follow-up and treatment planning for patients with mHSPC.
Conditions
- Metastatic Hormone-Sensitive Prostate Cancer
- Prostate Cancer
Interventions
Androgen Deprivation TherapyDrug
Androgen deprivation therapy used as part of routine first-line treatment for metastatic hormone-sensitive prostate cancer. Treatment was not assigned by the study.
ApalutamideDrug
Apalutamide used as part of routine first-line treatment for metastatic hormone-sensitive prostate cancer. Treatment was not assigned by the study.
EnzalutamideDrug
Enzalutamide used as part of routine first-line treatment for metastatic hormone-sensitive prostate cancer. Treatment was not assigned by the study.
DarolutamideDrug
Darolutamide used as part of routine first-line treatment for metastatic hormone-sensitive prostate cancer. Treatment was not assigned by the study.
RezvilutamideDrug
Rezvilutamide used as part of routine first-line treatment for metastatic hormone-sensitive prostate cancer. Treatment was not assigned by the study.
DocetaxelDrug
Docetaxel used as part of routine first-line treatment for metastatic hormone-sensitive prostate cancer. Treatment was not assigned by the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to deep PSA response (PSA ≤ 0.2 ng/mL)Time frame: From initiation of first-line therapy to the first PSA measurement ≤ 0.2 ng/mL, up to 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.